June 12, 2008 – Imaging Biometrics LLC (IB), a provider of advanced visualization and analytical software solutions, has an agreement with the American College of Radiology Imaging Network (ACRIN) to evaluate magnetic resonance imaging (MRI) datasets using its proprietary dynamic susceptibility contrast (DSC) MR perfusion software, IB Neuro.
The ACRIN trial is a global multicenter phase II trial using advanced imaging to track the effectiveness of biological treatments for brain tumors. IB Neuro uses DSC algorithms to provide information about blood volume and blood flow in the brain. These perfusion parameters are valuable for detecting new tumor growth or tumor recurrence, and should assist in tailoring personalized treatment plans for patients. MR perfusion imaging may also play an important role in the development of improved treatment therapies, another objective of this study.
ACRIN principal investigator Gregory Sorensen, M.D., Harvard professor and co-director of the A.A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital, said, “This study marries advanced imaging techniques with one of the most important topics in oncology today: antiangiogenic drugs. We hope that by doing this study we’ll understand better how antiangiogenic drugs work, how imaging can shed light on making decisions about therapeutic choices, and how to better develop improved treatments for cancer.”
For more information: www.imagingbiometrics.com